Why obesity must be treated as the root of cardiometabolic disease
We must treat obesity as the root of cardiometabolic disease, or it risks bankrupting global healthcare systems, explains Calibrate CEO Isabelle Kenyon.
Calibrate’s first product is a one-year metabolic reset. It is designed to bring decades of clinical research directly to consumers through a virtual programme combining US Food and Drug Administration (FDA)-approved prescription medication with intensive behaviour therapy delivered through one-on-one video coaching. In two years, Calibrate raised more than $125 million from leading investors, including Founders Fund, Tiger Global, Optum Ventures, Forerunner Ventures, Threshold Ventures, and Redesign Health. It has published clinically reviewed results from its Metabolic Reset that exceeded clinical trial outcomes across metabolic markers. Calibrate was designated as a World Economic Forum Technology Pioneer in 2021.